Evidence map›Paper›PMID 33534048›Full record

ArticleJournal of assisted reproduction and genetics2021

Growth hormone supplementation during ovarian stimulation improves oocyte and embryo outcomes in IVF/PGT-A cycles of women who are not poor responders.

Amanda Skillern, Whitney Leonard, Jordyn Pike, Winifred Mak

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of assisted reproduction and genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05447208 (A Randomized Control Trial to Investigate the Effect of Growth Hormone on the Euploid Rate of Blastocyst in Patients With Advanced Maternal Age), which is not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05447208 phase3recruitingnot on this mapstarted 2022, after this paper: background citation

A Randomized Control Trial to Investigate the Effect of Growth Hormone on the Euploid Rate of Blastocyst in Patients With Advanced Maternal Age

TypeinterventionalSponsorShangHai Ji Ai Genetics & IVF InstituteRan2022 to 2026Enrolled400ConditionsPreimplantation Genetic Testing, Growth Hormone, Age, ParentalArmsGrowth Hormone, GnRH antagonist
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Growth hormone supplementation in women who are not poor responders.Journal of assisted reproduction and genetics · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Amanda SkillernWomen's Health Department, Dell Medical School, UT Austin, Medical Park Tower, 1301 W. 38th Street, Suite 705, Austin, Texas, 78705, USA.
Whitney LeonardWomen's Health Department, Dell Medical School, UT Austin, Medical Park Tower, 1301 W. 38th Street, Suite 705, Austin, Texas, 78705, USA.
Jordyn PikeWomen's Health Department, Dell Medical School, UT Austin, Medical Park Tower, 1301 W. 38th Street, Suite 705, Austin, Texas, 78705, USA.
Winifred MakWomen's Health Department, Dell Medical School, UT Austin, Medical Park Tower, 1301 W. 38th Street, Suite 705, Austin, Texas, 78705, USA. winifred.mak@austin.utexas.edu.ORCID http://orcid.org/0000-0003-4885-4446
Dell Children's Medical Center of Central Texas · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo determine the effect of human growth hormone (GH) supplementation during ovarian stimulation in women undergoing IVF/PGT-A cycles, who do not meet the Bologna criteria for poor ovarian response (POR).

methodsThis is a retrospective cohort study of 41 women with suboptimal outcomes in their first cycle of IVF/PGT-A including lower than expected number of MII oocytes, poor blastulation rate, and/or lower than expected number of euploid embryos for their age, who underwent a subsequent IVF/PGT-A cycle with the same fixed dose gonadotropin protocol and adjuvant GH treatment. Daily cotreatment with GH started with first gonadotrophin injection. The IVF cycle outcomes were compared between the control and GH cycle using the Wilcoxon-Signed Rank test.

resultsThe total number of biopsied blastocysts (mean ± SD; 2.0 ± 1.6 vs 3.5 ± 3.2, p = 0.009) and euploid embryos (0.8 ± 1.0 vs 2.0 ± 2.8, p = 0.004) were significantly increased in the adjuvant GH cycle compared to the control cycle. The total number of MII oocytes also trended to be higher in the GH cycle (10.2 ± 6.3 vs 12.1 ± 8.3, p = 0.061). The overall blastulation and euploidy rate did not differ between the control and treatment cycle.

conclusionOur study uniquely investigated the use of adjuvant GH in IVF/PGT-A cycles in women without POR and without a priori suspicion for poor outcome based on their clinical parameters. Our study presents preliminary evidence that GH supplementation in these women is beneficial and is associated with an increased number of blastocysts for biopsy and greater number of euploid embryos for transfer.

Indexed as

Fertilization in VitroAdultBirth RateDietary SupplementsFemaleGrowth HormoneHumansLive BirthOocytesOvulation InductionPregnancyPregnancy RateSperm Injections, IntracytoplasmicGrowth HormoneGrowth hormoneIn-vitro fertilizationIVF/PGT-A

Identifiers

PMID33534048
PMCPMC8190221
OpenAlexW3128329591

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.